KRAS G12C INHIBITORS AND USES THEREOF

The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in...

Full description

Saved in:
Bibliographic Details
Main Authors ROSE, Tristin, E, BARTBERGER, Michael, D, SLAMON, Dennis, MCDERMOTT, Martina, S, REEVES, Corey, M, LOSON, Oliver, C, O'BRIEN, Neil, A, HILF, Justin, A, O'BOYLE, Brendan, M, STOLTZ, Brian, M
Format Patent
LanguageEnglish
French
German
Published 26.04.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.
Bibliography:Application Number: EP20200810811